Published in Gut on March 01, 1994
Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg (2006) 1.31
T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut (1997) 1.14
The immunogenicity of colorectal cancers with high-degree microsatellite instability. World J Surg Oncol (2005) 1.01
High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer (1997) 0.99
Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. Gut (1996) 0.96
Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand. Immunology (2008) 0.83
Interleukin 21 up-regulates perforin-mediated cytotoxic activity of human intra-epithelial lymphocytes. Immunology (2009) 0.81
Limited heterogeneity in the T-cell receptor V-gene usage in lymphocytes infiltrating human colorectal tumours. Br J Cancer (1994) 0.81
Image analyzer-based assessment of tumor-infiltrating T cell subsets and their prognostic values in colorectal carcinomas. PLoS One (2015) 0.79
Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut (1998) 0.75
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets. Immunol Today (1989) 5.86
Isolation and functional characterization of human intestinal mucosal lymphoid cells. J Clin Invest (1977) 5.09
Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature (1992) 4.86
Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med (1986) 3.99
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods (1987) 3.09
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 2.81
Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol (1986) 2.80
Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer (1987) 2.50
Lymphocyte homing. Adv Immunol (1989) 1.98
Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med (1988) 1.98
Determinants of the localization, magnitude, and duration of a specific mucosal IgA plasma cell response in enterically immunized rats. J Immunol (1982) 1.81
Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology (1990) 1.63
Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer (1984) 1.52
Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst (1991) 1.46
Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol (1991) 1.34
Specific and non-specific lymphocyte cytotoxicity in colon carcinoma. Br J Cancer (1981) 1.31
Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res (1991) 1.30
Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet (1989) 1.28
Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res (1991) 1.25
Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res (1987) 1.23
Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol (1987) 1.19
Primary and secondary human in vitro T-cell responses to soluble antigens are mediated by subsets bearing different CD45 isoforms. Immunology (1992) 1.17
Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J Immunol (1989) 1.13
Human CD8+ intraepithelial T lymphocytes are mainly CD45RA-RB+ and show increased co-expression of CD45R0 in celiac disease. Eur J Immunol (1990) 1.10
Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer (1992) 1.07
Selective loss of beta 2-microglobulin mRNA in human colon carcinoma. J Exp Med (1989) 0.99
Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol (1986) 0.97
Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer (1986) 0.96
Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res (1992) 0.96
Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes. Eur J Immunol (1992) 0.95
The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res (1992) 0.89
Oligoclonal T lymphocytes infiltrating human lung cancer tissues. Int J Cancer (1991) 0.89
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res (1991) 0.88
Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors. Int J Cancer (1990) 0.87
Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Res (1991) 0.87
Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol Immunother (1988) 0.85
Retracted An analysis of T-cell-receptor variable-region genes in tumor-infiltrating lymphocytes within malignant tumors. Int J Cancer (1991) 0.84
Signalling in human tumour infiltrating lymphocytes: the CD28 molecule is functional and is physically associated with the CD45R0 molecule. Eur J Cancer (1992) 0.77
Tumor-infiltrating lymphocytes: new therapy, new hopes. Gastroenterology (1990) 0.77
The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev (1992) 4.58
Isolation and partial characterization of major protein antigens in the culture fluid of Mycobacterium tuberculosis. Infect Immun (1991) 4.57
Properties of proteins MPB64, MPB70, and MPB80 of Mycobacterium bovis BCG. Infect Immun (1986) 3.80
Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet (2001) 3.71
The antigens of Mycobacterium bovis, strain BCG, studied by crossed immunoelectrophoresis: a reference system. Scand J Immunol (1980) 3.50
Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infect Immun (1988) 3.35
Purification, characterization and identification of a 32 kDa protein antigen of Mycobacterium bovis BCG. Microb Pathog (1987) 2.66
Evidence for absence of the MPB64 gene in some substrains of Mycobacterium bovis BCG. Infect Immun (1993) 2.50
MPB70, a unique antigen of Mycobacterium bovis BCG. Am Rev Respir Dis (1984) 2.45
MPB59, a widely cross-reacting protein of Mycobacterium bovis BCG. Int Arch Allergy Appl Immunol (1986) 2.25
Antibody response in rabbits to immunization with Mycobacterium leprae. Infect Immun (1977) 2.21
Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol (2003) 2.13
Purification, partial characterization, and identification of a skin-reactive protein antigen of Mycobacterium bovis BCG. Infect Immun (1987) 2.12
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol (1985) 2.06
Evidence for three separate genes encoding the proteins of the mycobacterial antigen 85 complex. Infect Immun (1990) 2.06
Antigens of PPD, old tuberculin, and autoclaved Mycobacterium bovis BCG studied by crossed immunoelectrophoresis. Am Rev Respir Dis (1981) 1.91
Quantitative and qualitative studies on the major extracellular antigen of Mycobacterium tuberculosis H37Rv and Mycobacterium bovis BCG. Am Rev Respir Dis (1990) 1.86
A localization index for distinction between extracellular and intracellular antigens of Mycobacterium tuberculosis. J Gen Microbiol (1991) 1.81
Purification and characterization of two protein antigens from the heterogeneous BCG85 complex in Mycobacterium bovis BCG. Int Arch Allergy Appl Immunol (1986) 1.79
Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Br J Surg (1998) 1.79
BCG antibody profiles in tuberculoid and lepromatous leprosy. Infect Immun (1974) 1.73
Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol (1985) 1.72
Recognition of two distinct groups of human IgM and IgA based on different binding to staphylococci. Scand J Immunol (1974) 1.70
Genetic and immunological analysis of Mycobacterium tuberculosis fibronectin-binding proteins. Infect Immun (1991) 1.69
Cross-reactions between mycobacteria. II. Crossed immunoelectrophoretic analysis of soluble antigens of BCG and comparison with other mycobacteria. Scand J Immunol (1979) 1.67
HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation--a fast and reliable technique. Tissue Antigens (1986) 1.67
Mycobacterium leprae specific antibodies detected by radioimmunoassay. Scand J Immunol (1978) 1.61
Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex. Science (1994) 1.59
Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest (1995) 1.57
The antigens of Mycobacterium tuberculosis, H37Rv, studied by crossed immunoelectrophoresis. Comparison with a reference system for Mycobacterium bovis, BCG. Scand J Immunol (1988) 1.56
Antigenic analysis of Mycobacterium leprae. Scand J Immunol (1979) 1.51
Magnetic monosized polymer particles for fast and specific fractionation of human mononuclear cells. Scand J Immunol (1985) 1.51
Dual role of mannan-binding protein in infections: another case of heterosis? Eur J Immunogenet (1994) 1.50
A family of cross-reacting proteins secreted by Mycobacterium tuberculosis. Scand J Immunol (1992) 1.41
[Study and diagnosis of pancreatic cancer]. Tidsskr Nor Laegeforen (1990) 1.39
Exclusive occurrence of K chains in isolated cold haemagglutinins. Scand J Haematol (1965) 1.38
Immunoglobulin class specific antibodies to M. leprae in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for sero-diagnosis of leprosy. Clin Exp Immunol (1982) 1.38
Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem (1992) 1.37
Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol (2009) 1.37
Production and assay of antibodies against one antigenic component of Mycobacterium bovis BCG. Infect Immun (1977) 1.33
Purification and characterization of the 30,000 dalton native antigen of Mycobacterium tuberculosis and characterization of six monoclonal antibodies reactive with a major epitope of this antigen. J Lab Clin Med (1991) 1.31
Antibody activity against Mycobacterium leprae antigen 7 during the first year of DDS treatment in lepromatous (BL-LL) leprosy. Lepr Rev (1978) 1.24
Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol (1998) 1.23
Immunochemical characterization of the MPB70/80 and MPB83 proteins of Mycobacterium bovis. Infect Immun (1998) 1.22
The activation of bovine pepsinogen. Sequence of the peptides released, identification of a pepsin inhibitor. J Biol Chem (1974) 1.21
Synthesis of donor type gamma-G-globulin following thymus transplantation in hypo-gamma-globulinaemia with severe lymphocytopenia. Scand J Haematol (1966) 1.20
Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum (1986) 1.20
In vitro stimulation of lymphocytes in leprosy patients, healthy contacts of leprosy patients, and subjects not exposed to leprosy. Comparison of an antigen fraction prepared from Mycobacterium leprae and tuberculin-purified protein derivative. Scand J Immunol (1982) 1.20
In situ characterization of mononuclear cells in rheumatoid tissues, using monoclonal antibodies. No reduction of T8-positive cells or augmentation in T4-positive cells. Scand J Immunol (1982) 1.17
Heterogenous expression of the related MPB70 and MPB83 proteins distinguish various substrains of Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv. Scand J Immunol (1996) 1.17
Binding of IgA to protein-A-containing staphylococci: relationship to subclasses. Scand J Immunol (1976) 1.16
Shared idiotypes of human peripheral blood B and T lymphocytes. J Immunol (1979) 1.16
Demonstration of mycobacterial antigens in nerve biopsies from leprosy patients using peroxidase-antiperoxidase immunoenzyme technique. Clin Immunol Immunopathol (1983) 1.16
Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol (1988) 1.15
Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol (1993) 1.15
Cold auto-agglutinins. Vox Sang (1971) 1.14
Characterization of a Mycobacterium leprae antigen related to the secreted Mycobacterium tuberculosis protein MPT32. Infect Immun (1994) 1.13
Characterization of human mononuclear cells after positive selection with immunomagnetic particles. Scand J Immunol (1986) 1.11
Molecular cloning of a T cell-specific adapter protein (TSAd) containing an Src homology (SH) 2 domain and putative SH3 and phosphotyrosine binding sites. J Biol Chem (1998) 1.11
Characterization of the secreted antigens of Mycobacterium bovis BCG: comparison of the 46-kilodalton dimeric protein with proteins MPB64 and MPB70. Infect Immun (1987) 1.10
Protein A reactivity of two distinct groups of human monoclonal IgM. Scand J Immunol (1975) 1.09
Comparative studies of antigen 21 in Mycobacterium and Nocardia species: possible taxonomic relationships with Mycobacterium leprae. Infect Immun (1980) 1.09
Formation of antibody against Mycobacterium leprae antigen 7 in armadillos. J Med Microbiol (1978) 1.08
Antibodies against BCG antigen 60 in mycobacterial infection. Br Med J (1977) 1.08
Production of monospecific antisera against antigenic componentsof Mycobacterium bovis (BCG). Scand J Immunol (1976) 1.08
Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex. J Biol Chem (1992) 1.08
In situ complement activation in porcine membranoproliferative glomerulonephritis type II. Kidney Int (1998) 1.07
Heterogeneity of monoclonal antibody-reactive epitopes on mycobacterial 30-kilodalton-region proteins and the secreted antigen 85 complex and demonstration of antigen 85B on the Mycobacterium leprae cell wall surface. Infect Immun (1992) 1.06
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer (2006) 1.05
Individual antigenic specificity of human macroglobulins: Localization of antigenic determinants and their use to demonstrate formation of hybrid molecules after reduction and reassociation. J Exp Med (1969) 1.04
Cross-reactivity of antigens from the cytoplasm and cell walls of some corynebacteria and mycobacteria. J Infect Dis (1985) 1.04
T cell-specific adapter protein inhibits T cell activation by modulating Lck activity. J Immunol (2000) 1.03
Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol (1995) 1.03
Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clin Exp Immunol (1986) 1.01
Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live Mycobacterium bovis BCG. Infect Immun (1993) 1.01
Family studies in individuals with selective absence of gamma-A-globulin. Clin Exp Immunol (1971) 1.01
Heat shock proteins: friend and foe? Clin Exp Immunol (1991) 1.00
Relationship of secretion pattern and MPB70 homology with osteoblast-specific factor 2 to osteitis following Mycobacterium bovis BCG vaccination. Infect Immun (1995) 1.00
Chronic autoimmune hemolytic anemia in childhood with cold antibodies, aplastic crises, and familial occurrence. Acta Paediatr Scand (1969) 1.00
Quantitation of cells secreting rheumatoid factor of IgG, IgA, and IgM class after elution from rheumatoid synovial tissue. Arthritis Rheum (1982) 0.99
Thymus dependent lymphocytes in leprosy. I. T lymphocyte subpopulations defined by monoclonal antibodies. Int J Lepr Other Mycobact Dis (1982) 0.98
Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. Scand J Immunol (1988) 0.98
Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia. Epidemiol Infect (2003) 0.98
Molecular and immunological characterization of the highly conserved antigen 84 from Mycobacterium tuberculosis and Mycobacterium leprae. Infect Immun (1995) 0.98
Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology. Scand J Immunol (1987) 0.98
Female genital tuberculosis in Ethiopia. Int J Gynaecol Obstet (2004) 0.97
Involvement of antilipoarabinomannan antibodies in classical complement activation in tuberculosis. Clin Diagn Lab Immunol (1998) 0.96
A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif Organs (1995) 0.95
Demonstration of mycobacterial antigens in leprosy tissues. Int J Lepr Other Mycobact Dis (1982) 0.95
Analysis of monoclonal antibodies to Mycobacterium leprae by crossed immunoelectrophoresis. Scand J Immunol (1987) 0.95
cAMP-dependent protein kinase (PKA) inhibits T cell activation by phosphorylating ser-43 of raf-1 in the MAPK/ERK pathway. Cell Signal (2000) 0.94
Molecular characterization of choline acetyltransferase from bovine brain caudate nucleus and some immunological properties of the highly purified enzyme. J Neurochem (1978) 0.94
Cloning, expression and significance of MPT53 for identification of secreted proteins of Mycobacterium tuberculosis. Microb Pathog (1999) 0.92
T-cell immunoregulatory functions in rheumatoid arthritis patients. Scand J Immunol (1983) 0.91
Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol (2008) 0.91